UNC Lineberger Comprehensive Cancer Center: Leukemia trials

The registry lists 22 Leukemia studies with UNC Lineberger Comprehensive Cancer Center as lead sponsor. 4 are open to participants now and 5 have results posted.

Phase 1 7Phase 2 6No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)RecruitingNCT07634653Not applicable
• DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsRecruitingNCT06296368Not applicable
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• RN-Led Palliative and Supportive Care InterventionCompletedNCT04570709Not applicableResults posted
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 2Results posted
• High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AMLCompletedNCT02768792Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
• Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T CellsWithdrawnNCT07071909Phase 1/2
• Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer SurvivorsCompletedNCT06171945Not applicable
• Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)TerminatedNCT04920188
• Chemotherapy-related Cognitive Impairment and Acute LeukemiaCompletedNCT04644419
• Precision Dosing of Tyrosine Kinase Inhibitors in CML PatientsCompletedNCT03885830
• Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML PatientsCompletedNCT03488862
• Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALLActive, not recruitingNCT03016377Phase 1
• Exercise and Quality of Life in Leukemia PatientsCompletedNCT02246907Not applicable
• Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard InductionCompletedNCT01578954Phase 1
• PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute LeukemiasCompletedNCT01169012Phase 1
• Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT00577694Phase 1
• Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic LeukemiaCompletedNCT00499759Not applicable
• Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerCompletedNCT00237627Phase 1/2